This Article Full Text Full Text (PDF) [Supplementary Material] Letters to the Editor: Submit a response Letters to the Editor: View responses Alert me when this article is cited Alert me when Letters to the Editor are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mochida, Y. Articles by Brown, P. R. Search for Related Content PubMed PubMed Citation Articles by Mochida, Y. Articles by Brown, P. R. Social Bookmarking                   What's this?

Alendronate Does Not Inhibit Early Bone Apposition to Hydroxyapatite-Coated Total Joint Implants

A Preliminary Study

Investigation performed at the Departments of Anatomic Pathology and Orthopaedic Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, and the Division of Comparative Medicine and the Department of Surgery, The Johns Hopkins Hospital, Baltimore, Maryland

Yuichi Mochida, MD
Thomas W. Bauer, MD, PhD
Toshihiro Akisue, MD, PhD
Departments of Anatomic Pathology and Orthopaedic Surgery, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Phillip R. Brown, DVM
Division of Comparative Medicine and Department of Surgery, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287

One or more of the authors has received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article. Funds were received in total or partial support of the research or clinical study presented in this article. The funding source was Stryker Howmedica Osteonics.

Background: Alendronate is a pyrophosphate analogue of bisphosphonate that has been shown to inhibit osteoclastic bone resorption. Bone formation and remodeling are necessary to establish initial fixation of uncemented implants, especially those coated with a bioactive surface such as hydroxyapatite. Because the process of bone-remodeling that culminates in new-bone formation is thought to be initiated by osteoclastic bone resorption, it is appropriate to test the influence of osteoclast-inhibiting medications on bone apposition to hydroxyapatite-coated implants.

Methods: Twelve dogs underwent staged bilateral total hip arthroplasty, with twenty weeks between the first and second operations, with use of a titanium-alloy femoral stem that had a proximal macrotextured surface and a plasma-sprayed hydroxyapatite coating. Six of the dogs received oral alendronate therapy from the time of the surgery until they were killed; the other six dogs were untreated controls. The animals were killed four weeks after the second operation. Sections from matched implant sites (proximal, middle, and distal) were histologically analyzed. The linear extent of bone apposition, the linear extent and the thickness of the hydroxyapatite coating, and the total amount of cortical and trabecular bone were measured with the use of an interactive image analysis system.

Results: There were no significant differences in radiographic or histologic findings between the two groups at either four or twenty-four weeks. Although the extent of the hydroxyapatite coating decreased significantly with time in both groups (p < 0.01), we identified no significant influence of alendronate on the extent of bone apposition, the extent or thickness of the hydroxyapatite coating, or the cortical or trabecular bone area around the implants.

Conclusions: Many patients who are receiving alendronate for osteoporosis or other disorders may also be candidates for cementless total joint arthroplasty. Although bone formation is generally thought to be initiated by and coupled with bone resorption, our results suggest that alendronate has no discernible effect on the initial fixation of or the short-term bone-remodeling around hydroxyapatite-coated femoral total joint implants.

CiteULike    Connotea    Del.icio.us    Facebook    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Hayashi, A. Fotovati, S. A. Ali, K. Oda, H. Oida, and M. Naito Prostaglandin EP4 receptor agonist augments fixation of hydroxyapatite-coated implants in a rat model of osteoporosis J Bone Joint Surg Br, August 1, 2005; 87-B(8): 1150 - 1156. [Abstract] [Full Text] [PDF]

				C. D. Morris and T. A. Einhorn Bisphosphonates in Orthopaedic Surgery J. Bone Joint Surg. Am., July 1, 2005; 87(7): 1609 - 1618. [Abstract] [Full Text] [PDF]

Letters to the Editor:

Stanford University Libraries' HighWire Press (TM) assists in the publication of JBJS Online.
Copyright © 2002 by The Journal of Bone and Joint Surgery, Inc. Online ISSN: 1535-1386.
The Journal of Bone and Joint Surgery®, JBJS®, JB&JS®, and eJBJS® are registered in the U.S. Patent and Trademark Office.